Tremelimumab does not improve survival in advanced melanoma

NEW YORK (Reuters Health) - Patients with advanced melanoma who received tremelimumab in a phase III trial had longer-lasting responses compared to patients who got standard chemotherapy, but no better overall survival.
Source: Modern Medicine - Category: Journals (General) Source Type: news